Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some hepatic adverse effect statements align with the provided label excerpt (5.4) and monitoring is generally supported, but many additional risk-factor and mechanistic claims are not supported by the provided label sections and are improperly attributed to FDA or labeling.
Category Scores
Accurate Statements
Tigecycline has been linked to liver damage, including elevated liver enzymes.
Supported by 5.4 Hepatic Adverse Effects (increases in transaminases and other hepatic lab abnormalities reported).
Tigecycline can cause liver failure in rare cases.
Supported by 5.4 (isolated cases of significant hepatic dysfunction and hepatic failure).
Patients taking tigecycline should be closely monitored for liver function.
Supported by 5.4 (abnormal liver function tests should be monitored for evidence of worsening hepatic function).
Unsupported Statements
According to the FDA, the risk of liver damage from tigecycline is higher in patients with pre-existing liver disease.
Not supported in the provided label excerpts (5.4, 2.2 hepatic impairment, 8.5 geriatric).
According to the FDA, the risk of liver damage from tigecycline is higher in patients taking other medications that can affect the liver.
Not supported as stated; 5.4 notes some cases involved multiple concomitant medications but does not claim a higher risk attributable to medications that affect the liver.
Patients with pre-existing liver disease (such as cirrhosis or hepatitis) are more susceptible to liver damage from tigecycline.
Not supported by the provided label excerpts.
A study published in the Journal of Clinical Pharmacology found that patients with liver disease were more likely to experience liver enzyme elevations while taking tigecycline.
External study claim; not supported by the provided label excerpts.
Older adults may be more vulnerable to liver damage from tigecycline due to age-related changes in liver function.
5.4/8.5 provided excerpts do not state increased vulnerability to hepatic injury due to age-related changes in liver function (8.5 only says greater sensitivity to some adverse events cannot be ruled out).
A study published in the Journal of Gerontology found that older adults were more likely to experience liver enzyme elevations while taking tigecycline.
External study claim; not supported by the provided label excerpts.
Patients taking other medications that can affect the liver (such as acetaminophen or statins) may be at increased risk of liver damage from tigecycline.
Not supported by the provided excerpt; 5.4 does not identify specific concomitant drugs or state increased risk based on hepatotoxic medication classes.
DrugPatentWatch.com states that tigecycline can interact with over 200 medications, including those that can affect the liver.
Not supported by the provided label excerpts.
Patients with kidney disease may be at increased risk of liver damage from tigecycline due to the potential for drug accumulation.
Not supported by the provided label excerpts.
A study published in the Journal of Clinical Pharmacology found that patients with kidney disease were more likely to experience liver enzyme elevations while taking tigecycline.
External study claim; not supported by the provided label excerpts.
Patients with HIV/AIDS may be at increased risk of liver damage from tigecycline due to the potential for drug interactions with antiretroviral medications.
Not supported by the provided label excerpts.
The HIV Medicine Association states that tigecycline can interact with antiretroviral medications, including those that can affect the liver.
Not supported by the provided label excerpts.
Tigecycline is metabolized by the liver.
Not supported by the provided label excerpts.
Tigecycline can cause liver damage through direct toxicity.
Mechanistic explanation not supported by the provided label excerpts.
Tigecycline can cause liver damage through indirect toxicity.
Mechanistic explanation not supported by the provided label excerpts.
Indirect toxicity from tigecycline includes increasing the levels of other medications that can affect the liver.
Mechanistic explanation not supported by the provided label excerpts.
Liver function should be monitored through regular blood tests, including liver enzyme levels.
5.4 supports monitoring for worsening hepatic function when abnormal liver tests develop, but the provided excerpt does not explicitly support routine/regular monitoring for all patients or monitoring frequency as stated.
Tigecycline is a glycylcycline antibiotic marketed as Tygacil.
Not supported in the provided label excerpts.
Contradictions
Important Omissions
Label-supported statement that hepatic dysfunction may occur after discontinuation of tigecycline (5.4) was not included in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overstated/unsupported risk-factor specificity (e.g., FDA-attributed higher risk with pre-existing liver disease, specific concomitant hepatotoxic drugs, kidney disease, HIV/antiretroviral interactions) could mislead risk assessment. However, the core hepatic adverse effect and general monitoring for abnormal liver tests are aligned with the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple extracted claims add risk-factor and mechanistic details not supported by the provided FDA label excerpts, including several claims improperly attributed to 'FDA'.
Suggested Improvement
Restrict hepatic adverse effect and monitoring statements to the wording supported by 5.4 (hepatic lab abnormalities, isolated hepatic failure, monitoring worsening hepatic function and evaluation of risk/benefit after abnormal tests; consider that hepatic dysfunction may occur after discontinuation). Remove or clearly qualify unsupported external-study and non-label risk-factor/mechanism claims.